Johnson & Johnson has unveiled new data from its respiratory syncytial virus (RSV) vaccine showing 80% protection against severe infection in over 65s - setting a high benchmark for rivals such as Pfizer and GlaxoSmithKline in what is forecast to become a $10bn market.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?